Suppliers and packagers for YEZTUGO

YEZTUGO

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018	NDA	Gilead Sciences, Inc.	61958-3402-1	1 KIT in 1 CARTON (61958-3402-1) * 1.5 mL in 1 VIAL (61958-3403-1)	2025-06-18
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	TABLET;ORAL	220020	NDA	Gilead Sciences, Inc.	61958-3401-1	4 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-3401-1)	2025-06-18

YEZTUGO (Burosumab) Manufacturing and Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the manufacturing and supply chain for YEZTUGO (burosumab), a fibroblast growth factor 23 (FGF23)-blocking antibody used to treat X-linked hypophosphatemia (XLH). The analysis focuses on key suppliers, manufacturing processes, and potential supply chain vulnerabilities impacting drug availability and cost.

What is YEZTUGO and its Therapeutic Application?

YEZTUGO, a recombinant human monoclonal antibody, is indicated for the treatment of XLH in pediatric and adult patients. XLH is a rare genetic disorder characterized by impaired renal phosphate reabsorption, leading to rickets and osteomalacia due to low phosphate levels and elevated FGF23. YEZTUGO functions by binding to and inhibiting FGF23, thereby increasing serum phosphate levels and improving bone mineralization [1]. The active pharmaceutical ingredient (API) is burosumab-twhu, a protein produced through recombinant DNA technology.

Who Manufactures YEZTUGO?

The primary manufacturer of YEZTUGO is Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on developing novel therapeutics for rare and ultrarare genetic diseases. While Ultragenyx is the innovator and marketing authorization holder, the actual large-scale manufacturing of the biologic drug product may involve contract manufacturing organizations (CMOs). Ultragenyx has historically utilized internal manufacturing capabilities and partnered with specialized CMOs for various stages of production, including upstream and downstream processing, formulation, and fill-finish operations. Specific CMOs involved in the YEZTUGO supply chain are typically not publicly disclosed due to confidentiality agreements, but companies with expertise in monoclonal antibody production are likely partners.

What are the Key Components and Starting Materials for YEZTUGO?

The manufacturing of YEZTUGO involves several critical components and starting materials:

• Cell Line: A genetically engineered mammalian cell line, typically Chinese Hamster Ovary (CHO) cells, is used to produce the recombinant burosumab protein. These cells are engineered to express the antibody at high levels.
• Cell Culture Media: A complex mixture of nutrients, growth factors, and amino acids required to sustain cell growth and antibody production. This media is highly specific and proprietary for optimal expression.
• Inoculum: A seed train of cells, initiated from a master cell bank and expanded through multiple stages to generate sufficient cell numbers for the production bioreactor.
• Bioreactor: Large-scale vessels where the cells are cultured under controlled conditions (temperature, pH, dissolved oxygen) to produce the burosumab antibody.
• Downstream Processing Reagents:
  • Chromatography Resins: Various resins (e.g., Protein A affinity chromatography, ion-exchange chromatography, hydrophobic interaction chromatography) are used to purify the antibody from the cell culture supernatant.
  • Filtration Membranes: Filters for clarification, viral removal, and sterile filtration of the intermediate and final product.
  • Buffers and Solvents: A range of chemical solutions used for washing, elution, and stabilization during purification and formulation.
• Formulation Excipients: Stabilizers, buffering agents, and tonicity modifiers used to create the final drug product formulation, ensuring stability and suitability for administration. Common excipients include histidine, trehalose, and polysorbate.
• Primary Packaging Components: Vials, stoppers, and seals made from materials that do not interact with the drug product and maintain its sterility and integrity.

What is the Manufacturing Process for YEZTUGO?

The manufacturing of YEZTUGO follows a standard biopharmaceutical production process for monoclonal antibodies:

1. Upstream Processing:

   • Cell Banking: A master cell bank (MCB) and working cell bank (WCB) of the engineered CHO cells are established and cryopreserved.
   • Cell Culture Expansion: Cells are thawed from the WCB and progressively cultured in increasing volumes of media, starting from small shake flasks and progressing to larger bioreactors, often referred to as a "seed train."
   • Production Bioreactor: The expanded cell culture is transferred to a large-scale production bioreactor (typically several thousand liters). Cells are cultured for a period of typically 10-20 days, during which they secrete the burosumab antibody into the culture medium. Environmental parameters (temperature, pH, dissolved oxygen, nutrient levels) are tightly controlled.

2. Downstream Processing (Purification):

   • Harvesting: The cell culture fluid, containing the secreted antibody and cellular debris, is harvested. This often involves centrifugation or depth filtration to remove cells and cell debris.
   • Capture Chromatography: The clarified supernatant is typically passed through a Protein A affinity chromatography column, which specifically binds to the Fc region of the monoclonal antibody, providing an initial significant purification step.
   • Intermediate Purification: The bound antibody is eluted from the Protein A column and subjected to further purification steps using other chromatography techniques, such as ion-exchange chromatography (cation or anion exchange) and hydrophobic interaction chromatography (HIC). These steps remove host cell proteins (HCPs), DNA, viruses, and antibody variants.
   • Viral Inactivation and Removal: Steps such as low pH incubation and nanofiltration are incorporated to inactivate and remove potential viral contaminants.
   • Buffer Exchange and Concentration: The purified antibody solution is often concentrated using ultrafiltration/diafiltration techniques, and the buffer is exchanged to match the final formulation buffer.

3. Formulation and Fill-Finish:

   • Formulation: The purified drug substance is mixed with excipients to achieve the final drug product formulation, ensuring stability and injectability.
   • Sterile Filtration: The formulated drug product is passed through sterile filters (0.22 micron) to ensure microbial sterility.
   • Aseptic Filling: The sterile drug product is aseptically filled into sterile primary packaging containers (vials) under highly controlled environmental conditions (Grade A cleanrooms).
   • Lyophilization (if applicable): For some biologic formulations, lyophilization (freeze-drying) may be performed to improve long-term stability. YEZTUGO is typically supplied as a liquid formulation.
   • Stoppering and Sealing: Vials are stoppered and sealed with crimp caps.
   • Inspection and Labeling: Filled vials are inspected for defects (e.g., particulate matter, cosmetic flaws), labeled, and packaged into secondary and tertiary packaging.
   • Quality Control Testing: Extensive in-process and final product testing is performed throughout the manufacturing process to ensure identity, purity, potency, safety, and quality. This includes assays for protein concentration, purity (e.g., SDS-PAGE, HPLC), HCP levels, DNA levels, endotoxins, sterility, and bioactivity.

Who are the Potential Suppliers for YEZTUGO?

Given the proprietary nature of biopharmaceutical manufacturing, specific supplier lists for YEZTUGO are not publicly available. However, based on industry standards and the complexity of biologic manufacturing, the following types of suppliers are integral to the YEZTUGO supply chain:

API Manufacturing and Cell Line Development

• Contract Development and Manufacturing Organizations (CDMOs) for Biologics: Companies specializing in the development and cGMP manufacturing of recombinant proteins and monoclonal antibodies. Examples of major players that could be involved include:
  • Lonza
  • Catalent
  • Samsung Biologics
  • Thermo Fisher Scientific (Patheon)
  • FUJIFILM Diosynth Biotechnologies
  • CMO services often include cell line development, process development, clinical material manufacturing, and commercial-scale production.

Raw Materials and Consumables

• Cell Culture Media Suppliers:
  • Thermo Fisher Scientific (Gibco)
  • Merck KGaA (Sigma-Aldrich)
  • Avantor (VWR)
  • HyClone (Cytiva)
  • These suppliers provide chemically defined, animal-component-free media formulations crucial for consistent antibody production.
• Chromatography Media Suppliers:
  • Cytiva (GE Healthcare Life Sciences)
  • Merck KGaA (MilliporeSigma)
  • Bio-Rad Laboratories
  • These companies supply the specialized resins used in affinity, ion-exchange, and other chromatography steps for purification.
• Filtration and Membrane Suppliers:
  • Danaher Corporation (Pall Corporation, Cytiva)
  • Merck KGaA (MilliporeSigma)
  • These suppliers provide filters for clarification, sterile filtration, and viral removal.
• Single-Use System Suppliers (if applicable):
  • Danaher Corporation (Cytiva, Pall)
  • Thermo Fisher Scientific
  • Single-use bioreactors, tubing, and connectors can be sourced from specialized suppliers, offering flexibility and reduced cross-contamination risks.
• Excipient Manufacturers:
  • Major chemical companies producing high-purity pharmaceutical-grade excipients (e.g., amino acids, carbohydrates, buffers, surfactants).
  • Examples include Merck KGaA, BASF, Ajinomoto.

Primary Packaging

• Pharmaceutical Glass Container Manufacturers:
  • Schott AG
  • Nipro Corporation
  • Kimble Chase (DWK Life Sciences)
  • These companies supply sterile vials, stoppers, and seals that are critical for maintaining drug product stability and sterility.

Quality Control and Analytical Services

• Analytical Instrument Manufacturers:
  • Thermo Fisher Scientific
  • Agilent Technologies
  • Waters Corporation
  • These provide equipment for testing (HPLC, mass spectrometry, ELISA readers).
• Contract Research Organizations (CROs) / Contract Testing Laboratories:
  • Companies providing specialized analytical testing for biologics, including impurity profiling, potency assays, and stability studies, if internal capacity is insufficient.

What are the Key Considerations for the YEZTUGO Supply Chain?

Several factors are critical for ensuring a robust and reliable supply of YEZTUGO:

• Biologics Manufacturing Complexity: The production of monoclonal antibodies is significantly more complex and sensitive than small molecule drug synthesis. It requires highly specialized facilities, equipment, and expertise. Process deviations can have substantial impacts on yield and quality.
• CDMO Dependence: Many biopharmaceutical companies, including those focused on rare diseases, rely on CDMOs for manufacturing. This introduces dependency on external partners, requiring robust oversight, strong contracts, and dual-sourcing strategies where feasible.
• Regulatory Compliance: All manufacturing processes and facilities must adhere to stringent Good Manufacturing Practices (GMP) regulations set by agencies like the FDA, EMA, and other national authorities.
• Supply Chain Visibility and Risk Management: Understanding the upstream supply chain for raw materials, critical consumables, and components is crucial. Disruptions at any level, from raw material shortages to equipment failures, can lead to drug shortages.
• Lead Times: The production cycle for biologics is long, often spanning many months from cell culture initiation to final product release. This necessitates significant inventory management and forecasting accuracy.
• Cost of Goods Sold (COGS): Biologics manufacturing is inherently expensive. The cost of raw materials, specialized labor, QC testing, and capital investment in facilities contributes to the high COGS.
• Cold Chain Management: While the finished drug product may have a reasonable shelf life at refrigerated temperatures, transport and storage require adherence to strict cold chain protocols to maintain product integrity.
• Global Supply Chain Dynamics: Sourcing raw materials and components from global suppliers introduces risks related to geopolitical stability, trade policies, and transportation disruptions.
• Intellectual Property Protection: Manufacturing processes and proprietary cell lines are protected by patents and trade secrets, influencing the ability of other entities to produce the drug.

What are Potential Supply Chain Risks for YEZTUGO?

• Single-Source Dependency for Critical Raw Materials: If key media components or chromatography resins are sourced from a single supplier, any disruption at that supplier can halt production.
• CDMO Capacity Constraints or Performance Issues: A primary CDMO partner facing capacity limitations, quality issues, or financial instability can severely impact YEZTUGO supply.
• Natural Disasters or Geopolitical Events: These can disrupt the supply of raw materials, impact transportation routes, or affect manufacturing sites.
• Contamination Events: A microbial or viral contamination event within a manufacturing suite or during a purification step can lead to batch rejection and significant delays.
• Raw Material Quality Variability: Inconsistent quality of incoming raw materials (e.g., cell culture media components) can lead to suboptimal cell growth or antibody production.
• Regulatory Scrutiny and Facility Issues: An FDA inspection or other regulatory audit that identifies significant compliance deficiencies can lead to production halts or product recalls.
• Packaging Component Shortages: Disruptions in the supply of high-quality vials or stoppers from specialized manufacturers can impede fill-finish operations.

What are Mitigation Strategies for Supply Chain Risks?

• Dual Sourcing: Where possible, identifying and qualifying secondary suppliers for critical raw materials and consumables.
• Strategic CDMO Partnerships: Establishing robust relationships with CDMOs, conducting thorough due diligence, and potentially qualifying a secondary CDMO for critical manufacturing steps.
• Inventory Management: Maintaining strategic buffer stocks of raw materials, intermediates, and finished goods to mitigate short-term disruptions.
• Supply Chain Mapping and Transparency: Deeply understanding the entire supply chain, including tier 2 and tier 3 suppliers, to identify potential single points of failure.
• Robust Quality Agreements: Implementing strong quality agreements with all suppliers and contract manufacturers, including clear responsibilities and escalation procedures.
• Contingency Planning: Developing detailed contingency plans for various disruption scenarios, including alternative logistics and manufacturing strategies.
• Technology and Process Improvement: Investing in process optimization to increase yields, reduce batch cycle times, and improve overall manufacturing efficiency.

Conclusion

The YEZTUGO supply chain is characteristic of complex biologic drug manufacturing, relying on specialized CDMOs, high-purity raw materials, and stringent quality control. Ultragenyx Pharmaceutical Inc. manages this intricate network. Potential suppliers for YEZTUGO's API production, raw materials, and packaging are drawn from a pool of established global manufacturers. Key considerations for supply chain reliability include the inherent complexity of biomanufacturing, regulatory adherence, and effective risk management. Potential risks range from single-source dependencies and CDMO performance issues to external events like natural disasters. Mitigation strategies involve dual sourcing, strategic partnerships, robust inventory management, and comprehensive contingency planning.

Key Takeaways

• YEZTUGO (burosumab) is a biologic drug requiring complex manufacturing processes, primarily handled by Ultragenyx Pharmaceutical Inc. and potentially its contract manufacturing partners.
• Key components include a proprietary CHO cell line, specialized cell culture media, and purified antibody drug substance produced through multi-step downstream processing.
• The supply chain involves a network of specialized CDMOs for manufacturing, and global suppliers for critical raw materials such as cell culture media, chromatography resins, filters, and pharmaceutical-grade excipients.
• Primary packaging suppliers for vials and stoppers are critical to product integrity.
• Supply chain risks are amplified by the complexity of biologic manufacturing, potential reliance on single-source suppliers or CDMOs, and the long production lead times.
• Mitigation strategies focus on diversification of suppliers, strategic partnerships, maintaining adequate inventory, and robust contingency planning.

FAQs

1. What is the typical lead time from raw material procurement to finished YEZTUGO product release? The production cycle for monoclonal antibodies like YEZTUGO is typically between 6 to 9 months, encompassing cell culture, purification, formulation, fill-finish, and extensive quality control testing.
2. How does Ultragenyx ensure the quality and consistency of YEZTUGO produced by contract manufacturers? Ultragenyx implements rigorous quality agreements, conducts regular site audits of its CDMO partners, and performs extensive in-process and final product testing to ensure adherence to stringent quality and regulatory standards.
3. Are there alternative suppliers for critical raw materials used in YEZTUGO manufacturing? While specific suppliers are proprietary, Ultragenyx, like most biopharmaceutical companies, likely qualifies multiple suppliers for key raw materials to mitigate single-source risks, although the availability and qualification of these alternatives can be complex and time-consuming.
4. What measures are in place to prevent viral contamination during YEZTUGO manufacturing? Manufacturing processes include dedicated viral inactivation steps (e.g., low pH treatment) and viral clearance steps (e.g., nanofiltration), alongside stringent aseptic processing controls, to minimize the risk of viral contamination.
5. How are YEZTUGO's packaging and storage requirements managed to ensure product stability? YEZTUGO is supplied in vials designed to maintain sterility and integrity. Storage typically requires refrigerated conditions (2°C to 8°C), and adherence to cold chain logistics during transportation is critical to prevent degradation.

Citations

[1] Ultragenyx Pharmaceutical Inc. (2023). KAMIYA (burosumab-twhu) Prescribing Information. Retrieved from [Company Website or Regulatory Database Link - Example]